UK

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

2 November 2023

New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing compensation regardless of sales volume.

Grow and diversify funding for prevention to boost the nation’s health and prosperity, urges landmark report

12 October 2023

Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.

Reimagining Prevention for a Healthier, More Prosperous Society

12 October 2023

In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary measures, can help to reduce ill health, improve healthcare capacity, and increase wider economic growth.

The changing role of the NHS over time

14 August 2023

OHE has been producing reports since 1962 which give insights into issues facing the NHS in the 75 years since it was created. The first part…

Can a continued focus on prevention, diagnosis, and treatment see the NHS to another 75 years?

27 July 2023

We have delved into the OHE archives to reflect on past NHS successes. In part one of a two-part Insight series, we look at three major contributors to shorter life expectancies – tuberculosis, heart disease, and cancer.

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

18 July 2023

The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS and wider society. The foreword has been provided by Angela Gibbons, patient and HS advocate.

This project has been organised and funded by Novartis Pharmaceuticals UK Ltd, with support from M+F Health. The report is informed by input from experts working in HS, including leading clinicians.

How Restrictive are NICE ‘Optimised’ Decisions?

27 April 2023

NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.

Combination Therapies: A Step Forward to the Value Attribution Problem

4 January 2023

OHE convened a roundtable discussion to present and discuss recent work by OHE colleagues and collaborators on value attribution frameworks for combination therapies.

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

16 June 2021

Our new paper explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there…